Immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is
central to long-term control of the current pandemic. Despite our rapidly advancing …

To successfully protect against pathogen infection, a vaccine must elicit efficient adaptive
immunity, including B and T cell responses. While B cell responses are key, as they can …

The efficacy of convalescent plasma for coronavirus disease 2019 (COVID-19) is unclear.
Although most randomized controlled trials have shown negative results, uncontrolled …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected 78 million
individuals and is responsible for over 1.7 million deaths to date. Infection is associated with …

The spike aspartic acid–614 to glycine (D614G) substitution is prevalent in global severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strains, but its effects on viral …

The durability of infection-induced SARS-CoV-2 immunity has major implications for
reinfection and vaccine development. Here, we show a comprehensive profile of antibody, B …

Antibody responses to SARS-CoV-2 can be detected in most infected individuals 10–15 d
after the onset of COVID-19 symptoms. However, due to the recent emergence of SARS …

In December 2019, the novel betacoronavirus Severe Acute Respiratory Disease
Coronavirus 2 (SARS-CoV-2) was first detected in Wuhan, China. SARS-CoV-2 has since …

Most individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) develop neutralizing antibodies that target the viral spike protein. In this study, we …

While the standard regimen of the BNT162b2 mRNA vaccine for SARS-CoV-2 includes two
doses administered 3 weeks apart, some public health authorities are spacing these doses …